ResMed (ASX: RMD) — Stock Profile

About ResMed (ASX: RMD)

ResMed develops, manufactures, and markets medical devices and cloud-based software applications for the diagnosis, treatment, and management of respiratory disorders, serving customers across the United States and internationally. The company operates through two segments, Sleep and Breathing Health and Residential Care Software, addressing clinical and home-based care settings through an integrated combination of hardware and digital health tools.

On the device and monitoring side, ResMed offers diagnostic products such as ApneaLink Air, NightOwl, and EasyCare Tx for sleep apnea assessment, alongside cloud-based platforms including AirView for remote patient monitoring and myAir for personalized therapy management. Its software portfolio spans several brands serving post-acute and home-based care providers, with Brightree supporting home medical equipment and pharmacy organizations, HEALTHCAREfirst serving home health and hospice agencies, MatrixCare providing electronic health record solutions for skilled nursing and senior living communities, and MEDIFOX DAN catering to residential and home health providers in additional markets. Founded in 1989, ResMed is headquartered in San Diego, California.

MFAM Research

  • [BUY] ResMed (ASX: RMD) – A New Product Cycle and a Cheap Multiple
    May 4, 2026
    ResMed reported its 3Q26 result this week. We are reiterating our Buy view on the stock with a price target of A$46.20, against a closing price of A$28.73 on 1 May 2026 and roughly 60.8 per cent upside to that target. The thesis is straightforward. Top-line growth keeps compounding through the GLP-1 overhang, gross margins […]
Our Exclusive Top 5 Stock Picks

Five high conviction stocks that didn't make the public list. Backed by institutional research with significant upside potential. Subscribe for free access.

Invalid email address
By subscribing, you consent to receive communications from us. You can unsubscribe at any time.

Latest Announcements

  • ResMed Inc (ASX: RMD) – ResMed Announces Dividend Distribution Payment
    May 1, 2026
    ResMed Inc has declared an ordinary quarterly dividend of USD 0.06 per Chess Depositary Instrument, which equates to USD 0.60 per underlying NYSE share given the 10:1 CDI structure. The dividend relates to the company’s first quarter of 2026, ending 31 March, and will be payable on 18 June 2026 to shareholders on the record […]
  • ResMed Inc (ASX: RMD) – ResMed Reports Q3 FY2026 Results
    May 1, 2026
    ResMed delivered 11 percent revenue growth to $1.4 billion in the third quarter of fiscal 2026, alongside meaningful margin expansion that reflects improving operational leverage across the company’s global business. Gross margins expanded by 290 basis points on a non-GAAP basis to 62.8 percent, a substantial move that demonstrates ResMed’s ability to scale efficiently while […]

Financial Summary

Price History

Same Industry — HealthcareSame Sub-Industry — Medical Instruments & Supplies
Share This